



Please distribute the attached customer letter.

To the Laboratory Manager

To the attention of the Healthcare center Chairman

To the attention of the Reactovigilance correspondent

Address
City, Date

Our reference: FSCA 3039

IMPORTANT:

PRODUCT SAFETY NOTICE

VIDAS® Estradiol II (ref. 30431)

Dear bioMérieux Customer,

Your laboratory has received or will receive one or more kit of VIDAS® Estradiol II ref 30431.

Following several notifications recently published by different MD-IVD manufacturer about the impact of the Fulvestrant molecule on the estradiol level evaluation, bioMérieux has conducted an internal investigation on this subject.

Description of the issue

The drug Fulvestrant has recently been shown to cross react with estradiol assays available on the market. This is due to the fact that the Fulvestrant molecule has a similar chemical structure to estradiol and cross-reacts with antibodies used in immunoassays.

Following an internal investigation it has been confirmed that the Fulvestrant molecule cross reacts with VIDAS® Estradiol II test ref.30431. It lead to an overestimation of estradiol level.

Table 1 : Dosages of Estradiol obtained with or without Fulvestrant with VIDAS instruments:

Instrument	17 - β -estradiol (pg/ml)	Control without Fulvestrant	Sample enriched with Fulvestrant (20000pg/ml)	% of cross reactivity*
miniVIDAS	20	28.42	65.83	0.19
	200	171.01	230.13	0.30
VIDAS	20	28.99	62.73	0.17
	200	172.67	227.71	0.28
VIDAS 3	20	27.72	59.75	0.16
	200	169.47	229.89	0.30

*Mean of all the % of cross reactivity obtained in all the runs performed with the defined parameters

A cross-reactivity study, carried out according to the principles of CLSI EP7-A2 guideline "Interference Testing in Clinical Chemistry; Approved Guideline – Second edition", has shown that the cross-reactivity percentage obtained for Fulvestrant is 0.32% maximum for a Fulvestrant® concentration of 20000 pg/ml.

BIOMERIEUX



This percentage was calculated with the following formula :

$$\frac{\text{mean value for the interference pool (with Fulvestrant)} - \text{mean value for the control pool (without Fulvestrant)}}{\text{interfering material concentration}} \times 100$$

Impact to customer:

The observed cross-reactivity induced in presence of Fulvestrant causes an overestimation of estradiol level when tested with VIDAS® Estradiol II assay.

Considering that Fulvestrant is indicated for:

1. Treatment of hormone receptor positive breast cancer in postmenopausal women whose breast cancer has worsened after they were treated with antiestrogen medications such as tamoxifen.
2. Treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.

If the VIDAS® Estradiol II assay is used to test a postmenopausal woman with a Fulvestrant treatment there is the potential to overestimate the patient estradiol level.

The resultant falsely elevated estradiol level could result in misinterpreting the patient as premenopausal or failing therapy and possibly lead to altered or discontinued use of the potentially beneficial drug Fulvestrant.

Required actions:

- Please distribute this information to all appropriate personnel in your laboratory, retain a copy in your files, and forward this information to all parties that may use this product, including others to whom you may have transferred our product.
- Do not use VIDAS® Estradiol II test to test estradiol level in patient under Fulvestrant therapy.
- The subject issue is related to VIDAS® Estradiol II test ref.30431, including the current and the future lots – not yet released – until Package Insert correction is implemented.
- Discuss any concern you may have regarding previously reported results with your Laboratory Medical Director to determine the appropriate course of action.
- Complete and return the Acknowledgement Form in Attachment A by Fax to confirm receipt of this notice.

bioMérieux is committed to providing our customers with the highest quality product possible. We sincerely apologize for any inconvenience that this may have caused you. If you require additional assistance or have any questions, please contact your local bioMérieux Customer Service representative.

Yours sincerely,
Customer Service

BIOMERIEUX



Attachment A: Acknowledgement Form.

FIELD SAFETY NOTIFICATION NOTICE

FSCA 3039 – VIDAS® ESTRADIOL II – Ref. 30431

TO BE RETURNED TO YOUR BIOMERIEUX CUSTOMER SERVICE AT THE FOLLOWING

FAX NUMBER : XXXXXXXX

Name of the laboratory:

City:

Customer number:

I acknowledge the receipt of bioMérieux Urgent Field Notice informing this company on the **VIDAS ESTRADIOL II – Ref. 30431** product limitation.

I have followed the instructions and implemented the actions as indicated in the Urgent Field Notice.

Have you received reports of illness or injury related to the identified issue?

Yes or No

DATE

SIGNATURE :

BIOMERIEUX